Department of Ophthalmology, Shanghai General Hospital, School of medicine, Shanghai Jiaotong University, Shanghai, China.
Acta Ophthalmol. 2020 Mar;98(2):e212-e216. doi: 10.1111/aos.14228. Epub 2019 Aug 17.
We determined vitreous and serum levels of high mobility group box-1 (HMGB-1) in patients with proliferative diabetic retinopathy (PDR) and elucidate their relationship with receptor for advanced glycation end products (RAGE), vascular endothelial growth factor (VEGF) and interleukin-1β (IL-1β).
In this cross-sectional study, patients with PDR who underwent vitrectomy were enrolled, and the control group included non-diabetic eyes. Vitreous and serum samples were analysed for HMGB-1, RAGE, VEGF and IL-1β by ELISA. We investigated the correlation between serum and vitreous levels of each cytokine, and we analysed the influence of intravitreal anti-VEGF treatment prior to vitrectomy on the cytokine levels in PDR.
Of 78 eyes of 78 patients enrolled consecutively, there were 32 PDR eyes and 46 control eyes. The serum levels were higher in diabetic than in non-diabetic subjects for HMGB-1, RAGE, VEGF and IL-1β (all p < 0.001), respectively. Similarly, the vitreous levels were higher in diabetic than in non-diabetic subjects for HMGB-1 (p < 0.001), RAGE (p = 0.001), VEGF (p < 0.001) and IL-1β (p < 0.001), respectively. We found a positive correlation between serum and vitreous levels of HMGB-1 in patient with PDR (p = 0.047, R = 0.353). There was a negative correlation between serum and vitreous levels of VEGF in patient with PDR (p = 0.001, R = -0.546). For the subgroup analysis, we detected that the vitreous levels of RAGE were significantly lower in patients who underwent anti-VEGF injection prior to vitrectomy than those who did not (p < 0.001).
Our findings suggest that HMGB-1 is involved in PDR disorders, and it may be a novel therapeutic target to inhibit progression of PDR.
我们测定了增生性糖尿病视网膜病变（PDR）患者玻璃体和血清中高迁移率族蛋白 B1（HMGB-1）的水平，并阐明其与晚期糖基化终产物受体（RAGE）、血管内皮生长因子（VEGF）和白细胞介素-1β（IL-1β）的关系。
在这项横断面研究中，我们纳入了接受玻璃体切除术的 PDR 患者，并以非糖尿病患者的眼作为对照组。通过 ELISA 分析玻璃体和血清样本中的 HMGB-1、RAGE、VEGF 和 IL-1β。我们研究了每种细胞因子血清和玻璃体水平之间的相关性，并分析了玻璃体切除术前玻璃体腔内抗 VEGF 治疗对 PDR 细胞因子水平的影响。
连续纳入的 78 例 78 只眼中，有 32 只 PDR 眼和 46 只对照组眼。HMGB-1、RAGE、VEGF 和 IL-1β 的血清水平在糖尿病患者中均高于非糖尿病患者（均 P<0.001）。同样，HMGB-1（p<0.001）、RAGE（p=0.001）、VEGF（p<0.001）和 IL-1β（p<0.001）在糖尿病患者的玻璃体水平也高于非糖尿病患者。我们发现 PDR 患者血清和玻璃体 HMGB-1 水平之间存在正相关（p=0.047，R=0.353）。PDR 患者血清和玻璃体 VEGF 水平之间存在负相关（p=0.001，R=-0.546）。在亚组分析中，我们发现，与未行玻璃体腔抗 VEGF 注射的患者相比，行玻璃体腔抗 VEGF 注射的患者的玻璃体 RAGE 水平显著降低（p<0.001）。
我们的研究结果表明，HMGB-1 参与了 PDR 病变，它可能是抑制 PDR 进展的一个新的治疗靶点。
